Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$3.80
-9.1%
$6.22
$4.00
▼
$1,272.00
$1.94M0.88105,008 shs831 shs
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.36
-6.7%
$3.72
$2.05
▼
$10.08
$2.45M0.7142,222 shs7,603 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$0.35
-9.4%
$3.92
$0.36
▼
$981.75
$683K-0.09689,259 shs154,844 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.64
+3.8%
$1.54
$1.10
▼
$10.43
$2.60M0.81167,521 shs8,071 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-9.72%-26.55%-35.46%-74.23%-99.56%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
+2.02%-8.00%-11.23%-43.55%-69.59%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-7.74%-11.40%-89.05%-97.36%-99.96%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-14.40%-3.37%+33.47%-48.70%-74.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$3.80
-9.1%
$6.22
$4.00
▼
$1,272.00
$1.94M0.88105,008 shs831 shs
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.36
-6.7%
$3.72
$2.05
▼
$10.08
$2.45M0.7142,222 shs7,603 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$0.35
-9.4%
$3.92
$0.36
▼
$981.75
$683K-0.09689,259 shs154,844 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$1.64
+3.8%
$1.54
$1.10
▼
$10.43
$2.60M0.81167,521 shs8,071 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-9.72%-26.55%-35.46%-74.23%-99.56%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
+2.02%-8.00%-11.23%-43.55%-69.59%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-7.74%-11.40%-89.05%-97.36%-99.96%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-14.40%-3.37%+33.47%-48.70%-74.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
1.00
SellN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
1.00
SellN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest JAGX, EOCN, CMND, and SILO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
Reiterated RatingSell (E+)
10/15/2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
Reiterated RatingSell (E+)
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$115.32 per shareN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/A$23.04 per shareN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$27.79M0.02N/AN/A($1,591.00) per share0.00
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$70K37.14N/AN/A$7.10 per share0.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$3.86M-$324.40N/AN/AN/AN/A-88.53%-61.62%N/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$10.31M-$15.18N/AN/AN/AN/A-73.68%-60.88%11/25/2026 (Estimated)
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$53.43M-$3,731.34N/AN/AN/A-187.88%N/A-131.45%N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$2.77N/AN/AN/A-6,726.39%-81.75%-66.35%12/2/2026 (Estimated)

Latest JAGX, EOCN, CMND, and SILO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.80N/AN/AN/A$0.02 millionN/A
11/25/2026N/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$3.12N/AN/AN/AN/AN/A
11/16/2026Q3 2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$444.29-$9.23+$435.06-$9.23$4.85 million$2.34 million
11/13/2026Q3 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.80-$0.21+$4.59-$0.21$0.02 millionN/A
9/10/2026Q3 2026
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$4.56N/A-$4.56N/AN/A
9/2/2026Q2 2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$3.12-$2.86+$0.26-$2.86N/AN/A
8/19/2026Q2 2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$782.25-$15.70+$766.55-$235.50$4.24 million$1.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.01
4.31
4.31
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/A
4.16
4.16
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.35
0.69
0.40
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
76.14%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%

Insider Ownership

CompanyInsider Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
19.80%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.12%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
4510,000N/ANot Optionable
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
201.04 million836,000Not Optionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
471.95 million1.94 millionNo Data
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
31.59 million1.53 millionNot Optionable

Recent News About These Companies

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$3.80 -0.38 (-9.11%)
As of 10:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:EOCN

$2.36 -0.17 (-6.72%)
As of 10:25 AM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$0.35 -0.04 (-9.42%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$1.64 +0.06 (+3.81%)
As of 10:34 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.